Historical record - last NADAC effective date: 4/17/2024
Product Information
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.1405 per EA under NDC 00054025422. Its NADAC has been published 547 times since Nov 28, 2013.
FDA first approved this application on Oct 15, 2012.
The Low Outlier badge above means this manufacturer's average price in the Irbesartan and Hydrochlorothiazide market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
12.5; 150 mg/1; mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054025422
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
4/17/2024
Active Ingredients
HYDROCHLOROTHIAZIDE; IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA090351FDA Approved
10/15/2012
On Market Since
10/15/2012
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has been published 547 times since Nov 28, 2013, and over the history we have for it it has declined 57.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1405 per EA |
|---|---|
| All-time high | $0.3512 (May 14, 2014) |
| All-time low | $0.1405 (Apr 17, 2024) |
| Median price | $0.2605 |
| Average price | $0.2563 |
| Largest weekly change | -25.0% (Nov 23, 2016) |
| Weeks tracked | 547 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-12.0%
5Y
-53.2%
All
-57.0%
Last surveyed May 15, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB, manufactured by Hikma Pharmaceuticals USA Inc., is $0.1405 per EA (NDC 00054025422), effective May 15, 2024.
How has the price of IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has declined 57.0%. It has been tracked across 547 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
Since Nov 28, 2013, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has ranged from a low of $0.1405 (Apr 17, 2024) to a high of $0.3512 (May 14, 2014), with a median of $0.2605 per EA.
Are there cheaper alternatives to IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB in a comparable dosage form, but none are currently priced below it.
Who manufactures IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB (NDC 00054025422) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.